Abstract
We have studied the structure and function of Human Misshapen / NIK-related kinase (MINK-1)through a combination of computational methods and experimental approaches,including (1)fold recognition and sequence-structure alignment for each structural domain using the threading program PROSPECT,(2)gene expression and protein-protein interaction analysis of yeast homologs of human MINK-1 domains,and (3)yeast two-hybrid screening for proteins that interact with human MINK-1.Our structure prediction dissects MINK-1 into four domains:a conserved N-terminal kinase domain,followed by a coiled-coil region and a proline-rich region,and a C- terminal GCK domain.Gene expression and yeast two-hybrid analysis of yeast homologs of the MINK-1 domains suggest that MINK-1 may be involved in cell-cycle progression and cytoskeletal control.Consistent with these predicted functions,our in-house yeast two-hybrid screen for proteins that interact with human MINK-1 provides strong evidence that the coiled-coil and proline-rich domains of MINK-1 participate in the regulation of cytoskeletal organization,cell-cycle control and apoptosis.A homology model of the MINK-1 kinase domain was used to screen the NCI open compound database in DOCK,and chemical compounds with pharmaceutically acceptable properties were identified.Further medicinal chemistry compound structure optimization and kinase assays are underway.
Keywords: mink, ste20-related kinases, gck domain, signal transduction, protein structure prediction, threading, yeast two-hybrid, gene expression, docking
Current Medicinal Chemistry
Title: Computational and Experimental Studies on Human Misshapen / NIK- Related Kinase MINK-1
Volume: 11 Issue: 5
Author(s): Kunbin Qu, Yanmei Lu, Nan Lin, Rajinder Singh, Xiang Xu, Donald G. Payan and Dong Xu
Affiliation:
Keywords: mink, ste20-related kinases, gck domain, signal transduction, protein structure prediction, threading, yeast two-hybrid, gene expression, docking
Abstract: We have studied the structure and function of Human Misshapen / NIK-related kinase (MINK-1)through a combination of computational methods and experimental approaches,including (1)fold recognition and sequence-structure alignment for each structural domain using the threading program PROSPECT,(2)gene expression and protein-protein interaction analysis of yeast homologs of human MINK-1 domains,and (3)yeast two-hybrid screening for proteins that interact with human MINK-1.Our structure prediction dissects MINK-1 into four domains:a conserved N-terminal kinase domain,followed by a coiled-coil region and a proline-rich region,and a C- terminal GCK domain.Gene expression and yeast two-hybrid analysis of yeast homologs of the MINK-1 domains suggest that MINK-1 may be involved in cell-cycle progression and cytoskeletal control.Consistent with these predicted functions,our in-house yeast two-hybrid screen for proteins that interact with human MINK-1 provides strong evidence that the coiled-coil and proline-rich domains of MINK-1 participate in the regulation of cytoskeletal organization,cell-cycle control and apoptosis.A homology model of the MINK-1 kinase domain was used to screen the NCI open compound database in DOCK,and chemical compounds with pharmaceutically acceptable properties were identified.Further medicinal chemistry compound structure optimization and kinase assays are underway.
Export Options
About this article
Cite this article as:
Qu Kunbin, Lu Yanmei, Lin Nan, Singh Rajinder, Xu Xiang, Payan G. Donald and Xu Dong, Computational and Experimental Studies on Human Misshapen / NIK- Related Kinase MINK-1, Current Medicinal Chemistry 2004; 11 (5) . https://dx.doi.org/10.2174/0929867043455873
DOI https://dx.doi.org/10.2174/0929867043455873 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preclinical Overview of WHI-07, A Novel Nucleoside Analog-based Dual- Function Microbicide
Current Medicinal Chemistry - Anti-Infective Agents Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?
Current Genomics miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Selective Cytotoxic Effects of 5-Trifluoromethoxy-<i>1H</i>-indole-2,3-dione 3-Thiosemicarbazone Derivatives on Lymphoid-originated Cells
Anti-Cancer Agents in Medicinal Chemistry Antisense Oligonucleotides as a Powerful Molecular Strategy for Gene Therapy in Cardiovascular Diseases
Current Pharmaceutical Design Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Olefin Metathesis as Key Step in the Synthesis of Bioactive Compounds: Challenges in the Total Synthesis of Iriomoteolides
Current Organic Synthesis Self-Assembled Micelles of Amphiphilic PEGylated Drugs for Cancer Treatment
Current Drug Targets AAV Hybrid Serotypes: Improved Vectors for Gene Delivery
Current Gene Therapy Nuclear Membranes GPCRs: Implication in Cardiovascular Health and Diseases
Current Vascular Pharmacology Development of Genomics-Based Gene Expression Signature Biomarkers in Oncology and Toxicology to Facilitate Drug Discovery and Translational Medicine
Current Bioinformatics Par-4 for Molecular Therapy of Prostate Cancer
Current Drug Targets Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Chromosomal Abnormalities, Cancer and Mouse Models The Critical Role of Translocation-Associated Genes in Human Cancer
Current Genomics Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals
Current Pharmaceutical Design Bcl-2 Antisense in the Treatment of Human Malignancies: A Delusion in Targeted Therapy
Current Pharmaceutical Biotechnology Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery
Current Topics in Medicinal Chemistry New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets